Oxford PV collaborates with HZB to move perovskite solar cells closer to commercialisation

Oxford PV – The Perovskite Company's industrial site in Brandenburg an der Havel, Germany where the company is working rapidly to transfer its advanced perovskite on silicon tandem solar cell technology to an industrial scale process.

Oxford PV – The Perovskite Company's industrial site in Brandenburg an der Havel, Germany where the company is working rapidly to transfer its advanced perovskite on silicon tandem solar cell technology to an industrial scale process. © Oxford PV

Perovskite solar technology leader Oxford PV collaborates with leading German research centre to support the accelerated transfer of its technology into silicon cell manufacturing lines.

Oxford PVTM – The Perovskite CompanyTM, the leader in the field of perovskite solar cells, today announced its collaboration with Helmholtz-Zentrum Berlin (HZB), the leading German research centre focused on energy materials research.

Oxford PV has made considerable progress in transferring its advanced perovskite on silicon tandem solar cell technology from its laboratory in Oxford, UK to an industrial scale process at its site in Brandenburg an der Havel, Germany.

HZB’s extensive expertise in silicon heterojunctions solar cell technology, will support Oxford PV to further optimise its perovskite on silicon tandem solar cell technology, and demonstrate production scale up, to ensure ease of integration into large scale silicon solar cell and module production.

“Working with HZB to understand solar cell manufacturers’ silicon cells, will allow Oxford PV’s perovskite on silicon tandem formation to be fully optimised, to ensure the most efficient tandem solar cell, and the easy transfer of our technology into our commercial partner’s industrial processes, commented Chris Case, Chief Technology Officer, at Oxford PV,

“Oxford PV is now in the final stage of commercialising its perovskite photovoltaic solution, which has the potential to enable efficiency gains that will transform the economics of silicon photovoltaic technology globally.”

Rutger Schlatmann, Director of the PVcomB institute at HZB, said, “HZB believe that perovskites present a significant opportunity to the future of photovoltaics. For this reason, at our new innovation lab - HySPRINT, we have significantly increased our expertise and attracted some of the most promising young scientists in this field. HZB’s collaboration with Oxford PV is strategically important to the institute, as Oxford PV is the ideal partner to further develop our solar cell technology knowledge and help support the commercialisation of tandem silicon perovskite photovoltaic cells.”

More Information:

  • Oxford PV
  • PVcomB
  • HySPRINT-a Helmholtz Innovation Lab

Oxford PV/HZB

  • Copy link

You might also be interested in

  • Two Humboldt-Fellows join HZB
    News
    09.12.2024
    Two Humboldt-Fellows join HZB
    In 2024, two young scientists joined HZB as Humboldt Fellows. Kazuki Morita joined Prof. Antonio Abate's group and brings his expertise in modelling and data analysis to solar energy research. Qingping Wu is an expert in battery research and works with Prof. Yan Lu on high energy density lithium metal batteries.
  • Less is more: Why an economical Iridium catalyst works so well
    Science Highlight
    05.12.2024
    Less is more: Why an economical Iridium catalyst works so well
    Iridium-based catalysts are needed to produce hydrogen using water electrolysis. Now, a team at HZB has shown that the newly developed P2X catalyst, which requires only a quarter of the Iridium, is as efficient and stable over time as the best commercial catalyst. Measurements at BESSY II have now revealed how the special chemical environment in the P2X catalyst during electrolysis promotes the oxygen evolution reaction during water splitting.
  • Protons against cancer: New research beamline for innovative radiotherapies
    News
    27.11.2024
    Protons against cancer: New research beamline for innovative radiotherapies
    Together with the University of the Bundeswehr Munich, the HZB has set up a new beamline for preclinical research. It will enable experiments on biological samples on innovative radiation therapies with protons.